Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques
Abstract The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2008-08, Vol.26 (34), p.4338-4344 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4344 |
|---|---|
| container_issue | 34 |
| container_start_page | 4338 |
| container_title | Vaccine |
| container_volume | 26 |
| creator | Moreno, A Caro-Aguilar, I Yazdani, S.S Shakri, A.R Lapp, S Strobert, E McClure, H Chitnis, C.E Galinski, M.R |
| description | Abstract The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli , recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII. |
| doi_str_mv | 10.1016/j.vaccine.2008.06.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2532489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X08007263</els_id><sourcerecordid>19807270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c647t-a481caf11273b8d77457325acec3f1083240d2ba6f0652de35172b653a98b2353</originalsourceid><addsrcrecordid>eNqFksuO1DAQRSMEYpqBTwB5A7s0ZTsPZzMIDU9pJEYCJHZWxalMu0nixk5a9Cfw1zh0aB6bWXlxj6-q7q0kecxhzYEXz7frPRpjB1oLALWGYg0c7iQrrkqZipyru8kKRJGlGYcvZ8mDELYAkEte3U_OuMpLKapqlfy49mQ6O1iDHcMQKISehpG5lo0bYlGk3eh8WtuhscMNa1yPdpjl6w5D7xo79Wxv9_idvZra9nACd96NFEkMDNkyKjMYxQZHYlHxGwpTYD0a_DZReJjca7EL9Gh5z5PPb15_unyXXn14-_7y5VVqiqwcU8wUN9hyLkpZq6Yss3mVHA0Z2XJQUmTQiBqLFopcNCRzXoq6yCVWqhYyl-fJxdF3N9U9NSZu67HTO2979Aft0Op_lcFu9I3ba5FHb1VFg2eLgXfz4KPubTDUdTiQm4IuKpkrXsCtIK8UlKKcwfwIGu9C8NSepuGg57b1Vi8R6rltDYWObcd_T_5e5c-vpd4IPF0ADLHg1uNgbDhxAiKnfmXy4shRDH5vyetgLA2GGhsvYNSNs7eOcvGfw--r-koHCls3-SG2qrkOQoP-OJ_mfJmgIGZQSPkTCpPi7A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19807270</pqid></control><display><type>article</type><title>Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moreno, A ; Caro-Aguilar, I ; Yazdani, S.S ; Shakri, A.R ; Lapp, S ; Strobert, E ; McClure, H ; Chitnis, C.E ; Galinski, M.R</creator><creatorcontrib>Moreno, A ; Caro-Aguilar, I ; Yazdani, S.S ; Shakri, A.R ; Lapp, S ; Strobert, E ; McClure, H ; Chitnis, C.E ; Galinski, M.R</creatorcontrib><description>Abstract The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli , recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2008.06.010</identifier><identifier>PMID: 18573299</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Adjuvant formulation ; Adjuvants, Immunologic - administration & dosage ; Allergy and Immunology ; Aluminum Hydroxide - administration & dosage ; Animals ; Antibodies, Protozoan - blood ; Antigens, Protozoan - immunology ; Applied microbiology ; Biological and medical sciences ; Duffy-binding protein ; Enzyme-Linked Immunosorbent Assay ; Escherichia coli ; Fundamental and applied biological sciences. Psychology ; Human protozoal diseases ; Infectious diseases ; Interferon-gamma - secretion ; Lymphocytes - immunology ; Macaca mulatta ; Malaria ; Malaria - prevention & control ; Malaria - veterinary ; Malaria vaccine ; Malaria Vaccines - immunology ; Mannitol - administration & dosage ; Mannitol - analogs & derivatives ; Medical sciences ; Microbiology ; Oleic Acids - administration & dosage ; Parasitic diseases ; Plasmodium vivax ; Protein Binding ; Protozoal diseases ; Protozoan Proteins - immunology ; Receptors, Cell Surface - immunology ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Synthetic - immunology]]></subject><ispartof>Vaccine, 2008-08, Vol.26 (34), p.4338-4344</ispartof><rights>Elsevier Ltd</rights><rights>2008 Elsevier Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c647t-a481caf11273b8d77457325acec3f1083240d2ba6f0652de35172b653a98b2353</citedby><cites>FETCH-LOGICAL-c647t-a481caf11273b8d77457325acec3f1083240d2ba6f0652de35172b653a98b2353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X08007263$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20573835$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18573299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno, A</creatorcontrib><creatorcontrib>Caro-Aguilar, I</creatorcontrib><creatorcontrib>Yazdani, S.S</creatorcontrib><creatorcontrib>Shakri, A.R</creatorcontrib><creatorcontrib>Lapp, S</creatorcontrib><creatorcontrib>Strobert, E</creatorcontrib><creatorcontrib>McClure, H</creatorcontrib><creatorcontrib>Chitnis, C.E</creatorcontrib><creatorcontrib>Galinski, M.R</creatorcontrib><title>Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli , recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII.</description><subject>Adjuvant formulation</subject><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Allergy and Immunology</subject><subject>Aluminum Hydroxide - administration & dosage</subject><subject>Animals</subject><subject>Antibodies, Protozoan - blood</subject><subject>Antigens, Protozoan - immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Duffy-binding protein</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Escherichia coli</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Human protozoal diseases</subject><subject>Infectious diseases</subject><subject>Interferon-gamma - secretion</subject><subject>Lymphocytes - immunology</subject><subject>Macaca mulatta</subject><subject>Malaria</subject><subject>Malaria - prevention & control</subject><subject>Malaria - veterinary</subject><subject>Malaria vaccine</subject><subject>Malaria Vaccines - immunology</subject><subject>Mannitol - administration & dosage</subject><subject>Mannitol - analogs & derivatives</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Oleic Acids - administration & dosage</subject><subject>Parasitic diseases</subject><subject>Plasmodium vivax</subject><subject>Protein Binding</subject><subject>Protozoal diseases</subject><subject>Protozoan Proteins - immunology</subject><subject>Receptors, Cell Surface - immunology</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksuO1DAQRSMEYpqBTwB5A7s0ZTsPZzMIDU9pJEYCJHZWxalMu0nixk5a9Cfw1zh0aB6bWXlxj6-q7q0kecxhzYEXz7frPRpjB1oLALWGYg0c7iQrrkqZipyru8kKRJGlGYcvZ8mDELYAkEte3U_OuMpLKapqlfy49mQ6O1iDHcMQKISehpG5lo0bYlGk3eh8WtuhscMNa1yPdpjl6w5D7xo79Wxv9_idvZra9nACd96NFEkMDNkyKjMYxQZHYlHxGwpTYD0a_DZReJjca7EL9Gh5z5PPb15_unyXXn14-_7y5VVqiqwcU8wUN9hyLkpZq6Yss3mVHA0Z2XJQUmTQiBqLFopcNCRzXoq6yCVWqhYyl-fJxdF3N9U9NSZu67HTO2979Aft0Op_lcFu9I3ba5FHb1VFg2eLgXfz4KPubTDUdTiQm4IuKpkrXsCtIK8UlKKcwfwIGu9C8NSepuGg57b1Vi8R6rltDYWObcd_T_5e5c-vpd4IPF0ADLHg1uNgbDhxAiKnfmXy4shRDH5vyetgLA2GGhsvYNSNs7eOcvGfw--r-koHCls3-SG2qrkOQoP-OJ_mfJmgIGZQSPkTCpPi7A</recordid><startdate>20080812</startdate><enddate>20080812</enddate><creator>Moreno, A</creator><creator>Caro-Aguilar, I</creator><creator>Yazdani, S.S</creator><creator>Shakri, A.R</creator><creator>Lapp, S</creator><creator>Strobert, E</creator><creator>McClure, H</creator><creator>Chitnis, C.E</creator><creator>Galinski, M.R</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>C1K</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080812</creationdate><title>Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques</title><author>Moreno, A ; Caro-Aguilar, I ; Yazdani, S.S ; Shakri, A.R ; Lapp, S ; Strobert, E ; McClure, H ; Chitnis, C.E ; Galinski, M.R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c647t-a481caf11273b8d77457325acec3f1083240d2ba6f0652de35172b653a98b2353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adjuvant formulation</topic><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Allergy and Immunology</topic><topic>Aluminum Hydroxide - administration & dosage</topic><topic>Animals</topic><topic>Antibodies, Protozoan - blood</topic><topic>Antigens, Protozoan - immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Duffy-binding protein</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Escherichia coli</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Human protozoal diseases</topic><topic>Infectious diseases</topic><topic>Interferon-gamma - secretion</topic><topic>Lymphocytes - immunology</topic><topic>Macaca mulatta</topic><topic>Malaria</topic><topic>Malaria - prevention & control</topic><topic>Malaria - veterinary</topic><topic>Malaria vaccine</topic><topic>Malaria Vaccines - immunology</topic><topic>Mannitol - administration & dosage</topic><topic>Mannitol - analogs & derivatives</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Oleic Acids - administration & dosage</topic><topic>Parasitic diseases</topic><topic>Plasmodium vivax</topic><topic>Protein Binding</topic><topic>Protozoal diseases</topic><topic>Protozoan Proteins - immunology</topic><topic>Receptors, Cell Surface - immunology</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno, A</creatorcontrib><creatorcontrib>Caro-Aguilar, I</creatorcontrib><creatorcontrib>Yazdani, S.S</creatorcontrib><creatorcontrib>Shakri, A.R</creatorcontrib><creatorcontrib>Lapp, S</creatorcontrib><creatorcontrib>Strobert, E</creatorcontrib><creatorcontrib>McClure, H</creatorcontrib><creatorcontrib>Chitnis, C.E</creatorcontrib><creatorcontrib>Galinski, M.R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno, A</au><au>Caro-Aguilar, I</au><au>Yazdani, S.S</au><au>Shakri, A.R</au><au>Lapp, S</au><au>Strobert, E</au><au>McClure, H</au><au>Chitnis, C.E</au><au>Galinski, M.R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2008-08-12</date><risdate>2008</risdate><volume>26</volume><issue>34</issue><spage>4338</spage><epage>4344</epage><pages>4338-4344</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli , recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18573299</pmid><doi>10.1016/j.vaccine.2008.06.010</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2008-08, Vol.26 (34), p.4338-4344 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2532489 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvant formulation Adjuvants, Immunologic - administration & dosage Allergy and Immunology Aluminum Hydroxide - administration & dosage Animals Antibodies, Protozoan - blood Antigens, Protozoan - immunology Applied microbiology Biological and medical sciences Duffy-binding protein Enzyme-Linked Immunosorbent Assay Escherichia coli Fundamental and applied biological sciences. Psychology Human protozoal diseases Infectious diseases Interferon-gamma - secretion Lymphocytes - immunology Macaca mulatta Malaria Malaria - prevention & control Malaria - veterinary Malaria vaccine Malaria Vaccines - immunology Mannitol - administration & dosage Mannitol - analogs & derivatives Medical sciences Microbiology Oleic Acids - administration & dosage Parasitic diseases Plasmodium vivax Protein Binding Protozoal diseases Protozoan Proteins - immunology Receptors, Cell Surface - immunology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - immunology |
| title | Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T03%3A11%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preclinical%20assessment%20of%20the%20receptor-binding%20domain%20of%20Plasmodium%20vivax%20Duffy-binding%20protein%20as%20a%20vaccine%20candidate%20in%20rhesus%20macaques&rft.jtitle=Vaccine&rft.au=Moreno,%20A&rft.date=2008-08-12&rft.volume=26&rft.issue=34&rft.spage=4338&rft.epage=4344&rft.pages=4338-4344&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2008.06.010&rft_dat=%3Cproquest_pubme%3E19807270%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19807270&rft_id=info:pmid/18573299&rft_els_id=1_s2_0_S0264410X08007263&rfr_iscdi=true |